

RECOMMENDATIONS

- 1- Evaluation of telomere length and telomerase expression is highly recommended for assessment of AML prognosis. However, standardization of the methods used for this evaluation, and cut-off values is a must to overcome the poor reproducibility among laboratories and to help in comparison between different researches.
- 2- Telomere length and telomerase proliferative indices could be used as predictive tests of AML outcome, and should be incorporated in prognostic indices assigned for prognosis and risk stratification of AML cases.
- 3- Detection of h-TERT by The **enzyme-linked immunosorbent assay (ELISA)** technique is a simple, less expensive and easily applied method for evaluation of telomerase proliferative activity in AML and may replace the more commonly used PCR assay in routine daily work.
- 4- Further selected studies including larger number of different FAB subtypes, correlation with other parameters as molecular parameters and gene profiling are needed to assess telomere and telomerase expression in individual subtypes and this may be of help for selection of the appropriate anti-telomerase therapy for each type.
- 5- The assessment of telomere length and telomerase expressions may become one of the crucial parameters for deciding which therapy is best for individual cases of AML. However, large studies concerning this point and ongoing collaboration between basic scientists and clinical researchers are definitely needed before this new therapeutic modality becomes a reality in the field of AML treatment.

REFERENCES

1. Burnett AK and Venditti A . Acute myeloid leukaemia. In: Hoffbrand AV, Catovsky D and Tuddenham E (eds) Post graduate Haematology. Sixth edition. Blackwell Publishing Ltd.UK 2011; 23: 415-33.
2. Mrozek K, Heerema NA. Cytogenetics in acute leukemia. *Blood Journal* 2004; 18:115–136.
3. Gross M, Mkrtychyan H, Glaser M, Fricke HJ, Hoffken K, Heller A, Weise A and Liehr T. Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. *International Journal of Oncology* 2009; 34: 417–423.
4. Miller D, Reynolds GE, Mejia R, Stark JM and Murnane JP. Subtelomeric regions in mammalian cells are deficient in DNA doublestrand break repair. *DNA Repair* 2011; 10: 536–544.
5. Murnane, J.P. Telomere dysfunction and chromosome instability. *Mutat Res.* 2012; 730(1-2):28-36.
6. Pennaneach, V., Putnam, C.D. & Kolodner, R.D. Chromosome healing by de novo telomere addition in *Saccharomyces cerevisiae*. *Molecular Microbiology* 2006; 59: 1357–1368.
7. Charles H. Telomeres, telomerase, and cancer. *NEJM* 2000; 342: 1282-83.
8. Klapper W, Krams M, Qian W, Janssen D , Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. *Br J Cancer* 2003; 89: 713-9.
9. Wong JMY, Collins K. Telomerase maintenance and disease. *Lancet* 2003; 362: 293.
10. Bryce LA. Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. *Neoplasia* 2000; 2: 197–201.
11. Sabah M, Robert C, Mary L, Elaine K. Immunohistochemical detection of hTERT protein in soft tissue sarcomas: correlation With tumor grade. *Appl immunohistochem molec morphol* 2006; 14(2): 198-202.
12. Olausson KA, Dubrana K, Domont J, Spano J, Sabatier L, Charles J. Telomeres and telomerase as targets for anticancer drug development. *Clin Rev Oncol Hematol* 2006; 57(3):191-214.
13. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. *Oncogene.* 2002; 21(4) : 680–7.

14. Briatore F, Barrera G, Pizzimenti S, Toaldo C, Casa CD, Laurora S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. *Cancer Biol Ther.* 2009; 8(10):883–9.
15. Deville L, Hillion J, Ségal-Bendirdjian E. Telomerase regulation in hematological cancers: a matter of stemness? *Biochim Biophys Acta.* 2009; 1792(4):229–39.
16. Baird, D.M. New developments in telomere length analysis. *Experimental Gerontology* 2005; 40: 363–368.
17. Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clinical burden of acute myeloid leukemia. *Expert Rev Anticancer Ther.* 2003; 3:695–710.
18. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. *Cancer* 2003; 97(12 Suppl):3133–3275.
19. Smith BD and Sung L. Acute myeloid leukemia. *The American Society of Hematology* 2013. 481-9.
20. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. *CA Cancer J Clin.* 2002 ; 52 :23–47.
21. Ries LAG EM, Kosary CL, Hankey BF, et al., editors. *SEER Cancer Statistics Review, 1975–2000.* Bethesda, MD: National Cancer Institute; 2003. Available at URL: http://seer.cancer.gov/csr/1975_2000 [accessed June 2004].
22. Alieldin N. Cancer statistics at National Cancer Institute, Cairo; 2002-2010: Cancer statistics for specific site; cancers of genitourinary system. [online]. 2007 [cited 2012 Jun 29]. Available from: URL: <http://www.nci.edu.eg/lectures/NCI/registry/2002-10.doc>.
23. Deschler B, Lübbert M. Acute Myeloid Leukemia: Epidemiology and Etiology. *Cancer.* 2006; 107: 2099-107.
24. Potzsch C, Voigtlander T, Lubbert M. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and threemetachronous malignancies. *J Cancer Res Clin Oncol.* 2002; 128:456–460.
25. Pogoda JM, Preston-Martin S, Nichols PW, Ross RK. Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study. *Am J Epidemiol.* 2002;155:546–553.
26. Kerr JR, Barah F, Cunniffe VS, et al. Association of acute parvovirus B19 infection with new onset of acute lymphoblastic and myeloblastic leukaemia. *J Clin Pathol.* 2003;56:873–875.
27. Carli PM, Sgro C, Parchin-Geneste N, et al. Increase therapy-related leukemia secondary to breast cancer. *Leukemia.*2000;14:1014–1017.
28. Baer MR and Greer JP. Acute Myeloid Leukemia in Adults. In: Greer JP, Foerster J and Rodgers GM (eds) *Wintrobe's Clinical Hematology.* 12th Edition. Lippincott Williams & Wilkins Philadelphia USA. 2009, pp. 1843 -89.

29. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed). Lyon, France: International Agency for Research on Cancer; 2008.
30. Bain BJ and Haferlach T. Laboratory diagnosis of haematological neoplasms. In: Hoffbrand AV, Catovsky D and Tuddenham E (eds) Post graduate Haematology. Sixth edition. Blackwell Publishing Ltd.UK 2011; 22: 395-414.
31. Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 9th ed. Library of Congress Cataloging, London. 2001, pp. 297-314.
32. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol*. 2003;21:4642–4649.
33. Albitar M and Donahue A. Molecular pathology of leukemia. In: O'Brien SM, Vose JM and Kantarjian HM (eds) Management of Hematologic Malignancies. First edition. Cambridge University Press UK 2011; 1: 1-26.
34. Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. *Expert Rev Hematol*. 2012 October; 5(5): 547–58.
35. Redner RL. Variations on a theme: the alternate translocations in APL. *Leukemia* 2002;16:1927–32.
36. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. *Blood* 2005;106:3768–76.
37. Dohner H, Estey EH, Amadori S, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. *Blood*. 2010; 115(3):453–74.
38. Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. *Leuk Lymphoma* 2007;48:1472–81.
39. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. *Blood*. 2007; 110(4): 1262–70.
40. Wagner K, Damm F, Thol F, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. *Haematologica*. 2011; 96(5):681–686.
41. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood*. 2011;117(12):3294–301.

42. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010;28(4):596–604.
43. Schlenk RF, Dohner K, Krauter J, et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia: results of the AMLSG 07-04 randomized treatment trial. *ASH Annual Meet Abstr*. 2011; 118(21):80.
44. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBP α differentiation pathway in human cancer. *J Clin Oncol*. 2009; 27(4):619–628.
45. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. *J Clin Oncol*. 2008; 26(31):5078–5087.
46. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α -ketoglutarate to 2-hydroxyglutarate. *Cancer Cell*. 2010; 17(3):225–34.
47. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med*. 2003; 349(21):2042–54.
48. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. *Blood*. 2001; 97(5):1172–1179.
49. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. *Haematologica*. 2008; 93(7):976–82.
50. Mendler JH, Maharry K, Radmacher MD, et al. Poor outcome of RUNX1-mutated (RUNX1-mut) patients (Pts) with primary, cytogenetically normal acute myeloid leukemia (CN-AML) and associated gene- and microRNA (miR) expression signatures. *ASH Annual Meet Abstr*. 2011; 118(21):3454.
51. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell*. 1990; 60(3):509–520.
52. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. *Hum Mol Genet*. 2006; 15(Spec No 2):R196–R201.
53. Yang L, Han Y, Suarez Saiz F, Saurez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. *Leukemia*. 2007; 21(5):868–76.
54. Gaidzik VI, Schlenk RF, Moschny S, et al. German-Austrian AML Study Group. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German–Austrian AML Study Group. *Blood*. 2009; 113(19):4505–4511.

55. Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. *Curr Opin Hematol.* 2002; 9(4):282–287.
56. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. *J Clin Oncol.* 2002;20(15):3254–61.
57. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. *Blood.* 2005; 106(1):345–52.
58. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. *N Engl J Med.* 2009; 360(22):2289–2301.
59. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. *Nat Genet.* 2009; 41(7):838–842.
60. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European Leukemia Net risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol.* 2011; 29(10):1373–81.
61. Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. *J Clin Oncol.* 2012;30(12):1350–57.
62. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. *Leukemia.* 2009; 23(11):2183–2186.
63. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *Br J Haematol.* 2009; 145(6): 788–800.
64. Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. *J Clin Oncol.* 2011; 29(18):2499–506.
65. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. *Blood.* 2011; 118(26):6920–9.
66. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. *Leukemia.* 2008; 22(8):1539–41.
67. Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. *J Clin Oncol.* 2008; 26(28):4603–9.
68. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004; 116(2):281–97.

69. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. *Proc Natl Acad Sci USA*. 2008; 105(10):3945–50.
70. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010; 28(36):5257–64.
71. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. *Blood*. 2008; 111(6):3183–9.
72. Wheatley K. A systemic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia. *Br J Haematol* 1998;103:100–9.
73. Heuser M, Argiropoulos B, Kuchenbauer F. MNI overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. *Blood* 2007; 110 (5):1639–47.
74. Hills R, Green C, Patel Y. The impact of FLT3-ITD and NPM1 mutational status on the outcome of ATRA therapy in patients with non-APL AML: results of the UK MRC AML12 trial. *Blood* 2008;112(11):554a.
75. Guy C, Gilkes A, Gale R. The impact of MN1 overexpression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy. *Blood* 2008; 112(11):2978a.
76. Milligan D, Wheatley K, Littlewood TJ. For the NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. *Blood* 2006; 107: 4614–22.
77. Bradstock KF, Matthews JP, Lowenthal RM. A randomized trial of high versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. *Blood* 2005;105(2):481–8.
78. Burnett AK, Wheatley K, Goldstone AH. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML10 trial. *Br J Haematol* 2002; 118:385–400.
79. Burnett AK, Hills RK, Wheatley K. A sensitive risk score for directing treatment in younger patients with AML. *Blood* 2006;108(11):10a
80. Estey E, de Lima M, Tibes R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Blood* 2007; 109(4):1395–400.

81. Breems DA, van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol* 2005;23(9):1969–78.
82. Burnett AK, Hills R, Goldstone AH, et al. The impact of transplant in AML in 2nd CR: a prospective study of 741 in the MRC AML10 and 12 trials. *Blood* 2004; 104 (11): 179a.
83. Tan P, Wei A, Mithraprabhu S, Cummings N and Perugini M. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood Cancer Journal* (2014) 4, e170.
84. Malik P and Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients. *Cancer Management and Research* 2014;6 :53–61.
85. Thomas X, Raffoux E, Botton S. Effect of priming with granulocyte macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. *Leukemia* 2007;21(3):453–61.
86. Knapper S. FLT3 inhibition in acute myeloid leukemia. *Br J Haematol* 2007; 138 (6): 687–99.
87. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. *Blood* 2006;107(9):3463–8.
88. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. *Semin Oncol* 2008; 35(4):388–400.
89. Feldman EJ, Brandwein J, Stone R. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. *J Clin Oncol* 2005; 23(28):4110–16.
90. Wadleigh M, Richardson PG, Zahrieh D. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. *Blood* 2003; 102(5):1578–82.
91. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood* 2003; 102 (7): 2379 –86.
92. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. *J Clin Oncol* published online April 12, 2010, DOI: 10.1200/JCO.2009.26.4242.
93. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome *Blood* 2008; 112:1638–45.

94. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. *Blood* 2007;109 (4):1387–94.
95. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. *J Clin Oncol* 2007;25(1):25–31.
96. Granger MP, Wright WE, and Shay JW. Telomerase in cancer and aging *Critical rev oncol/hematol* 2002; 41(1): 29-40.
97. Charles M. Telomeres, Telomerase, and Cancer. *NEJM* 2000; 342: 1282-3.
98. Dikmen ZG, Ozgurtas T, Gryaznov SM and Herbert B. Targeting critical steps of cancer metastasis and recurrence using telomerase template antagonists. *Molec basis disease* 2009;1792: 240-47.
99. Went P, Agostinelli C, Gallamini A. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. *J Clin Oncol* 2006;24:2472-2479.
100. Zou BY, Shay JW, Wright WE. Telomere position effect in human cells. *Science* 2001; 292: 2075–77.
101. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. *Oncogene* 2002; 21: 650.
102. Blackburn EH. Telomere states and cell fates. *Nature* 2000; 408:53–56.
103. Lange DL. Protection of mammalian telomeres. *Oncogene* 2002; 21:532–40.
104. Collins K and Mitchell J R. Telomerase in the human organism. *Oncogene* 2002; 21: 564–79.
105. Lange D. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev* 2005;.19:2100–10.
106. Blasco MA, Hahn WC. Evolving views of telomerase and cancer. *Trends in Cell Biol* 2003; 13 (6): 289-294.
107. Deville L, Hillion J, Segal-Bendirdjian E. Telomerase regulation in hematological cancers: A matter of stemness? (BBA)- *Molec basis of disease*. 2009; 1792: 229-39.
108. Hoster E, Dreyling M, Klapper W. German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood* 2008;111:558–65.
109. Espejel, S, Blasco MA. Identification of telomere-dependent ‘senescence-like’ arrest in mouse embryonic fibroblasts. *Exp. Cell Res* 2002; 276: 242–248.

110. Pendino FI, Tarkanyi C, Dudognon C, Hillion J, Lanotte M, Aradi J, Segal-Bendirdjian E. Telomeres and telomerase: pharmacological targets for new anticancer strategies?, *Curr Cancer Drug Targets* 2006;6:147–180.
111. Cristofari G, Lingner J. Telomere length homeostasis requires that telomerase levels are limiting, *EMBOJ* 2006; 25: 565–74.
112. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M Segal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance, *Oncogene* 2004;23: 7469–74.
113. Liu L, DiGirolamo CM, Navarro PA, Blasco MA and Keefe DL. Telomerase deficiency impairs differentiation of mesenchymal stem cells. *Exp. Cell Res.* 2004; 294: 1–8.
114. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. *Cancer Res* 2000; 6: 537–41.
115. Shin KH, Kang MK, Dicterow E, Park NH. Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. *Br J Cancer* 2003; 89: 1473–78.
116. Bellon M, Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. *J Natl Cancer Inst*; 2008;100: 98–108.
117. Ferber MJ, Montoya DP, Yu C, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. *Oncogene* 2003; 22: 3813–20.
118. Paterlini-Brechot P, Saigo k, Murakami Y et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. *Oncogene* 2003; 22: 3911–16.
119. Yang F, Xian RR, Li Y, Polony TS, Beemon KL. Telomerase reverse transcriptase expression elevated by avian leukosis virus integration in B cell lymphoma. *Proc Natl Acad Sci USA* 2007; 104: 18952–57.
120. Artandi S.E. Telomere dysfunction promotes nonreciprocal translocations and epithelial cancers in mice. *Nature* 2000; 406, 461–65.
121. Smogorzewska A, De Lange T. Different telomere damage signaling pathways in human and mouse cells. *EMBO J* 2002; 21: 4338–48.
122. Seger YR. Transformation of normal human cells in the absence of telomerase activation. *Cancer Cell* 2002; 2: 401–13.
123. Saeboe-Larssen S, Fossberg E, Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumor tissues, *BMC Mol. Biol* 2006;7.

124. Roser F, Saini M, Meliss R. Apoptosis, vascularity, and proliferation in primary central nervous system lymphomas (PCNSL): a histopathological study. *Surg Neurol* 2004; 62:393–399.
125. Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan ZM, Whang Y, Strauss W, Pandita TK, Weaver D, Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. *Curr Biol* 2000; 10: 568–575.
126. Geisler CH, Kolstad A, Laurell A. For the Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. *Blood* 2008; 112(7):2687–2693.
127. Wang F, Podell ER, Zaug AJ, Yang Y, Baciu P, Cech TR, Lei M. The POT1–TPP1 telomere complex is a telomerase processivity factor. *Nature* 2007; 445: 506–10.
128. Ghosh U, Das N, Bhattacharyya NP. Inhibition of telomerase activity by reduction of poly(ADP-ribosylation) of TERT and TEP1/TP1 expression in HeLa cells with knocked down poly (ADP-ribose) polymerase-1 (PARP-1) gene. *Mutat Res* 2007; 615; 66–74.
129. Azzalin M, Reichenbach P, Khoriantuli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends, *Science* 2007; 318: 798–801.
130. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. *Nat Cell Biol* 2008; 10:228–36.
131. Wu YY, Hruszkewycz AM, Delgado RM, Yang A, Vortmeyer Ao, Moon YW, Weil RJ, Zhuang Z and Remaley AT. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. *Clin Chim Acta* 2000; 293: 199-212.
132. Hammam OA, Shaker OG, Saleh A, El Leithy TR, Wishahi MM. Detection of Telomerase Activity Using a Quantitative Assay and immunohistochemistry Techniques In Urinary Bladder Lesions. *Aust J Basic & App Sci* 2008; 2(3): 518-26.
133. Fan Y, Liu Z, Fang X, Ge N, Jia Y, Sun P, Lou F, Bjorkholm M, Gruber A, Ekam P Xu D. Differential Expression of full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity between Normal and Malignant Renal Tissues. *Clin Cancer Res* 2005; 11(12): 4331-37.
134. Kim YJ, Park YN, Choi J, Kim KS, Park C. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV- related hepatocarcinogenesis. *Am j Gastroenterol* 2006; 4:101: 831.
135. Khalbuss W Goodison S. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. *J Cyto* 2006; 3: 18-25.

136. Hiyama E, Saeki T, Hiyama K. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples. *Cancer Cytopathol.* 2000; 90: 235–38.
137. Granger MP, Wright WE, Shay JW. Telomerase in cancer and aging. *Critical Rev Oncol/Hematol* 2002; 41(1): 29-40.
138. Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M and Luzi P. Evaluation of telomerase activity in cutaneous melanocytic proliferations. *Hum. Pathol* 2000; 31: 1018–21.
139. Herbert B, Wright WE, Shay JW. Telomerase and breast cancer. *Breast Cancer Res.* 2001; 3(3):146-9.
140. Jady BE, Bertrand E, Kiss T. Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal, *J. Cell Biol* 2004;164: 647–652.
141. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. *Cancer Res* 2005; 65: 7866–73.
142. Xiao HH, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. *Clin Cancer Res* 2006; 12: 3184–92.
143. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, Wright WE, Shay JW. Antiadhesive effects of GRN163L—an oligonucleotide N3'-P5' thiophosphoramidate targeting telomerase. *Cancer Res* 2007; 67: 1121–29.
144. Vonderheide H. Prospects and challenges of building a cancer vaccine targeting telomerase. *Biochimie* 2008; 90: 173–80.
145. Minev B. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. *Proc Natl Acad Sci* 2000; 97: 4796–4801.
146. Lansdorp, P M, Dragowska W, Thomas T E, Little MT, Mayani H. Age-related decline in proliferative potential of purified stem cell candidates. *Blood Cells* 1994; 20: 376–81.
147. Martens UM, Brass V, Sedlacek L, Pantic M, Exner C, Guo Y, Engelhardt M, Lansdorp P M, Waller C F, Lange W. Telomere maintenance in human B lymphocytes. *Br. J. Haematol* 2002; 119: 810–18.
148. Son NH, Murray S, Yanovski J, Hodes R J, Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B Lymphocytes with age. *J. Immunol.* 2000; 165:1191–6.
149. Gančarčíková M., Zemanová Z, Březinová J, Berková A, Včelíková S, Šmigová J and Michalová K. The Role of Telomeres and Telomerase Complex in Haematological Neoplasia: The Length of Telomeres as a Marker of Carcinogenesis and Prognosis of Disease. *Prague Medical Report* 2010; 111 (2):91–105.

150. Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi S, Shay J W, Ohyashiki K. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. *Clin. Cancer Res.* 1999, 5:1155–60.
151. Siegllová Z, Zilovcová S, Cermák J, Ríhová H, Brezinová D, Dvoráková R, Marková, M, Maaloufová J, Sajdová J, Brezinová J, Zemanová Z, Michalová K. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. *Leuk. Res.* 2004; 28: 1013–21.
152. Bakalova R, Ohba H, Zhelev Z, Kubo T, Fujii M, Ishikawa M, Shinohara Y, Baba Y. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. *FEBS Lett.* 2004; 564: 73–84.
153. Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. *Proc. Natl. Acad. Sci.* 1997;94: 13782–85.
154. Baerlocher G M, Rovó A, Müller A, Matthey S, Stern M, Halter J, Heim D, Rischewski J, Gratwohl A, Tichelli A. Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex. *Blood* 2009; 114: 219–22.
155. Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens M F, D'Incalci M, Blasco M, Chiorino G, Bauwens S, Horard B, Gilson E, Stoppacciaro A, Zupi G, Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. *J. Clin. Invest.* 2007; 117: 3236–47.
156. Baer MR, Greer JP. Acute myeloid leukaemia in adults. In: Wintrobe's clinical haematology. Greer JP, Foerster J, Luken JN (eds). 12th ed. Lippincott William's and Wilkin's publishers, Philadelphia USA. 2009, pp. 1843 -89.
157. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Elsevier Saunders Company, St Louis. 2006, pp. 797-825 (renal function tests), 604-14 (liver function tests).
158. Bates I, Lewis SM. Reference ranges and normal values. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 11th ed. Library of Congress Cataloging, London. 2011, pp. 11-23.
159. Bates I, Burthem J. Bone marrow biopsy. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 11th ed. Library of Congress Cataloging, London. 2011, pp. 123-39.
160. Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 11th ed. Library of Congress Cataloging, London. 2011, pp. 353-.

161. Porika M, Tippani R, Mohammad A, Bollam SR, Panuganti SD, Abbagani S. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer. *Int J Biol Markers* 2011; 26(1):22-6.
162. Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic Acids Res* 2002; 30(10): e47.
163. Olesen LH, Aggerholm A, Andersen BL, et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. *Br J Haematol* 2005; 131:457.
164. Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. *Blood* 2004; 103:4036.
165. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 2002; 100:4325-36.
166. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. *Oncogene* 2002;21:680-7.
167. Samassekou O, Ntwari A, Hébert J and Yan J. Individual Telomere Lengths in Chronic Myeloid Leukemia. *Neoplasia* 2009 ;11: 1146–54.
168. Engelhardt M, Mackenzie K, Drullinsky P and Silver R. Telomerase Activity and Telomere Length in Acute and Chronic Leukemia, Pre and Post-*ex Vivo* Culture. *CANCER RESEARCH* 2000; 60: 610–17.(13)
169. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood* 2010; 116:354.
170. Meng CY, Noor PJ, Ismail A, Ahid MF, Zakaria Z. Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia. *Int J Biomed Sci.* 2013;9(1):26-32.
171. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012; 62:10.
172. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. *Cancer* 2005; 104:788.
173. Samassekou O, Ntwari A, Hébert J and Yan J. Individual Telomere Lengths in Chronic Myeloid Leukemia. *Neoplasia* 2009 ;11: 1146–54.
174. Hiyamaa E, Hiyamab K. Telomerase as tumor marker. *Cancer Letters* 2003; 194: 221–33.
175. Koyanagi Y, Kobayashi D, Yajima T, Asanuma K, Kimura T, Sato T, Kida T, Yagihashi A, Kameshima H, Watanabe N. Telomerase activity is down regulated via

- decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells, *Anticancer Res* 2000; 20: 773–778.
176. Hiyama E, Hiyama K, Yokoyama T, Shay JW. Immunohistochemical Detection of Telomerase (hTERT) Protein in Human Cancer Tissues and a Subset of Cells in Normal Tissues. *Neoplasia* 2001; 3(1): 17–26.
 177. Porika M, Tippani R, Bollam SR, Panuganti SD, Thamidala C, Abbagani S. Serum human telomerase reverse transcriptase : a novel biomarker for breast cancer diagnosis. *Int J Clin Oncol* 2011; 16:617–22.
 178. Peter JFS, Roderick HJB, Thomas GS et al. Elevated hTERT mRNA levels: a potential determinant of bronchial squamous cell carcinoma (in situ). *Int J Cancer* 2004; 109:412–417.
 179. Liliana T, Enrica R, Salvatore P et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. *Clin Cancer Res* 2008; 14:7444–7451.
 180. Salhab M, Jiang WG, Newbold RF et al. The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. *Breast Cancer Res Treat* 2008; 109:35–46.
 181. Li YR, Wu JM, Wang L et al. Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma. *Acta Otolaryngol* 2005; 125:409–414.
 182. Miura N, Kanamori Y, Takahashi M et al. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. *Oncol Rep* 2007; 17:541–548.
 183. Miura N, Maeda Y, Kanbe T et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. *Clin Cancer Res* 2005; 11:3205–3209.
 184. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. *Haematologica* 2005; 90: 307–316.
 185. Seol, J. G., Kim, E. S., Park, W. H., Jung, C. W., Kim, B. K., and Lee, Y. Y. Telomerase activity in acute myelogenous leukemia: clinical and biological implications. *Br. J. Haematol.* 1998; 100: 156–165.
 186. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). *Gene* 2001; 269:1-12.
 187. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. *Int J Cancer* 2004;108:704-11

-
188. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. *Br J Haematol* 1998;102:1367-75
 189. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. *Neoplasia* 2000;2:433-40.
 190. Swiggers SJ, Kuijpers MA, de Cort MJ, Beverloo HB, Zijlmans JM. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. *Genes Chromosomes Cancer* 2006; 45: 247–256.
 191. Aalbers AM, Calado RT, Young NS, Zwaan CM. Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. *Leukemia* 2013; 27: 1786–9.
 192. Boultonwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. *Blood* 2000;96:358-61.
 193. Tukun A, Akay G and Kutlay N. Telomere and telomerase in hematological malignancies. *Turk J Hematol* 2006; 23:77-83 **REVIEW ARTICLE**
 194. White LK, Wright WE, Shay HW. Telomerase inhibitors. *Trends Biotechnol* 2001; 19: 114–20.
 195. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. *Oncogene* 2002; 21(4): 680–7.
 196. Olausson KA, Dubrana K, Domont J, Spano J, Sabatier L, Charles J. Telomeres and telomerase as targets for anticancer drug development. *Crit Rev Oncol Hematol* 2006; 57(3):191-214.
 197. Remes K, Norrback KF, Rosenquist R, Mehle C, Lindh J, Roos G. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. *Br J Cancer* 2000; 82: 601–607.
 198. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. *Haematologica* 2008; 93:594-600.
 199. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. *Semin Oncol* 2008;35:430-8.
 200. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. *Br J Haematol* 2011; 152:524-42.
 201. Hyeon G Y, Moon H L, Chul S K, Junsik H, Jinny P, Hoon L. Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. *Blood Res* 2014; 49:95-9.

طول التيلومير ومستوى الناسخ العكسى البشرى للتيلوميريز فى مرضى سرطان الدم النقوى الحاد
و اثرهما على المحصلة الاكلينيكية

Telomere Length and Human Telomerase Reverse Transcriptase (hTERT) Level in Patients with Acute Myeloid Leukemia: Impact on Clinical Outcome

Protocol of a thesis submitted to the
Medical Research Institute
University of Alexandria
in partial fulfillment of the
requirements for the degree of

خطة بحث مقدمة الى
معهد البحوث الطبية
جامعة الإسكندرية
إيفاء جزئياً لشروط
الحصول على درجة

Medical Doctorate in Clinical Haematopathology

الدكتوراه فى باثولوجيا أمراض الدم

By
Hayat Kalifa Fadlalla Ahmed
M.B.B.Ch
Faculty of Medicine
University of Alexandria
2001

من
حياة خليفة فضل الله احمد
بكالوريوس الطب والجراحة
كلية الطب
جامعة الإسكندرية
٢٠٠١

M.Sc. in Clinical Haematology
Faculty of Medicine
University of Alexandria
2007

ماجستير أمراض الدم
كلية الطب
جامعة الإسكندرية
٢٠٠٧

Assistant Lecturer
Department of Haematology
Medical Research Institute
University of Alexandria

مدرس مساعد
قسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

Department of Haematology
Medical Research Institute
University of Alexandria

قسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

Supervisors**المشرفون**

Dr Samia Farag Mohamed EL-Belbessy
 Professor, Department of Haematology
 Medical Research Institute
 University of Alexandria

الدكتورة سامية فرج محمد البلبيسى
 أستاذ بقسم أمراض الدم
 معهد البحوث الطبية
 جامعة الإسكندرية

Dr Hanaa Abd El-Meguid El-Aggan
 Professor, Department of Haematology
 Medical Research Institute
 University of Alexandria

الدكتورة هناء عبد المجيد العجان
 أستاذ بقسم أمراض الدم
 معهد البحوث الطبية
 جامعة الإسكندرية

Dr Hala Kassem Sultan
 Assistant Professor, Department of Haematology
 Medical Research Institute
 University of Alexandria

الدكتورة هالة قاسم سلطان
 أستاذ مساعد بقسم أمراض الدم
 معهد البحوث الطبية
 جامعة الإسكندرية

Dr. Amel Aly El Naggar
 Assistant Consultant, Department of Haematology
 Medical Research Institute
 University of Alexandria

الدكتورة أمل على النجار
 مساعد استشارى بقسم امراض الدم
 معهد البحوث الطبية
 جامعة الإسكندرية

Background

Acute myeloid leukemia (AML) is a malignant clonal disorder of immature cells in the haemopoietic hierarchical system. Leukaemic transformation is assumed to occur in many cases at, or near, the level of the haemopoietic stem cell before it has embarked on any lineage commitment. Some cases may originate at a slightly later stage in cells that are committed to lineage differentiation.⁽¹⁾

The more carefully AML is studied, the clearer it becomes that there is considerable heterogeneity between cases with respect to morphology, immunological phenotype, associated cytogenetic, molecular abnormalities and more recently, patterns of gene expression. This is reflected in the substantially different responses to treatment.⁽¹⁾

Numerous chromosomal aberrations have been documented in acute leukaemias. The underlying mechanisms that drive genomic instability and create the diversity on which clonal selection can operate have not been fully established. However, various lines of evidence have emerged that are consistent with telomere erosion and dysfunction as one possible mechanism driving genomic instability in AML.⁽²⁾

Whilst 55% of AML patients exhibit at least one cytogenetically detectable lesion at diagnosis, the remaining 45% do not. It was apparent that 50% of those cases that exhibit normal karyotypes show cryptic sub-microscopic losses or duplications of sub-telomeric DNA encompassing up to 600 kb.⁽³⁾

Subtelomeric deletion can arise as a consequence of either a subtelomeric double-stranded DNA break, as these regions are more sensitive to breaks, or the resection of short dysfunctional telomeres. The sub-telomeric break can then be 'healed' by the addition of TTAGGG repeats mediated by telomerase creating a new telomere and thus stabilizing the sub-telomeric deletion.⁽⁴⁻⁶⁾

Telomeres are specialized nucleoprotein structures at the ends of chromosomes; their function is to protect chromosomes from DNA breakage and to prevent chromosome fusion. Without new synthesis telomeres undergo progressive shortening with each cell division, leading to replicative senescence of cells. Shortening of telomeres can result in telomere end fusions and increase chromosomal instability which is a key initiating event in numerous cancers. ⁽⁷⁾

Telomerase is an enzyme that extends telomeric repeats on the ends of chromosomes. Activation of telomerase enzyme is therefore required for cells to overcome replicative senescence and to be able to divide indefinitely. Telomerase activity is expressed in germ cells and is present at low level in stem cells, but is usually absent in most somatic cells. Conversely, in immortal cancer cells, telomerase is reactivated, and telomeres are not shortened, suggesting that telomere elongation might be an essential step in tumor formation. ^(8,9)

Recently genes encoding three major components of human telomerase (TA) have been cloned : human telomerase RNA component (hTR), human telomerase reverse transcriptase (hTERT), and telomerase-associated protein 1 (TAP1). TERT is a telomerase catalytic subunit that is considered as the key component for the control of telomerase activity. ^(10,11)

Induction of hTERT expression is essential for telomerase activation during cellular immortalization and tumor progression. Several studies found a relationship between levels of hTERT expression, telomerase activity and clinical aggressiveness of a variety of malignancies. In the present study, we will examine hTERT expression in serum using enzyme linked immunosorbent assay (ELISA). ⁽¹²⁻¹⁵⁾

Telomere length (TL) is a key determinant of telomere function. Accurate techniques to measure TL in human tissues have provided a greater understanding of the role of telomeres in the progression to malignancy. Several techniques are available but the most commonly used are

terminal restriction fragment (TRF) analysis, quantitative fluorescence in situ hybridization (Q-FISH), flow-FISH, single TL analysis (STELA) and telomeric Q-PCR.⁽¹⁶⁾

The degree of telomere shortening varies in AML according to French-American-British (FAB) subtype, with the more differentiated subtypes showing increased shortening, though M5 shows the most pronounced telomere shortening and telomere shortening appears to be more marked in patients with cytogenetic alterations in comparison with normal karyotypes.⁽¹⁷⁾

Targeting the hTERT catalytic subunit as anticancer therapy is theoretically tumor-specific and might be less toxic due to its specific expression in tumor and highly proliferating cells compared to other normal cells. Various newly discovered agents represent interesting anti-hTERT candidates for clinical drug development.⁽¹²⁾

Aim of the Work

The aim of the present work is to study telomere length and human telomerase reverse transcriptase (hTERT) level in acute myeloid leukemia and to detect if these parameters might be useful in providing insight into the clinical outcome of AML patients.

Subjects and Methods

Subjects

After the consent of the Ethical Committee of the Medical Research Institute, seventy individuals will be included in the study and divided as follows:

Group I (control group):

It will include twenty healthy individuals with comparable age and sex.

Group II:

It will include fifty patients with acute myeloid leukemia.

Inclusion criteria:

Newly diagnosed acute myeloid leukemia cases either De novo or secondary to myelodysplastic syndrome and myeloproliferative neoplasms in patients older than 16 years will be included in the study. Patients will be subdivided according to French-American-British (FAB) classification.

Exclusion criteria:

Acute myeloid leukemia cases younger than 16 years.

The patients will be treated according to the standard chemotherapy protocol for induction and they will be followed up by bone marrow examination at day 14 and day 28 to determine patient's response. A complete response (CR) was defined as the presence of <5% blasts in a standardized bone marrow puncture after the second course of induction therapy with a fully regenerated peripheral blood count. ⁽¹⁸⁾

Methods

All subjects participating in this study will be subjected to the following:

I- Thorough history taking.

II- Thorough clinical examination.

III- Routine work up:

- Renal function tests⁽¹⁹⁾
- Liver function tests⁽¹⁹⁾
- Radiological work up (chest X-ray, U/S abdomen & pelvis and ECHO)

IV- Diagnostic laboratory investigations

a- Complete blood picture (CBP)⁽²⁰⁾

CBP from 2.5 ml EDTA-anticoagulated blood will be done using automated cell counter. The blood films will be prepared, stained by Leishman stain and then examined for differential WBC and RBC morphology.

b- Bone marrow examination⁽²¹⁾

Bone marrow aspiration will be done for all patients either from sternum or posterior iliac crest. Marrow aspirates will be then smeared on glass slides and stained by Leishman stain.

c- Immunophenotyping⁽²²⁾

Bone marrow or blood samples (2-3 mL) with heparin anticoagulation from patients will be obtained, and immunophenotypes will be identified by flow cytometry using monoclonal antibodies directed to antigens for T cells, B cells, myeloid cells [CD13, CD33, CD117 and myeloperoxidase (MPO)], monocytes (CD14 and CD64), erythroid cells (alpha-glycophorin), platelet cells (CD61 and

CD41a), non-specific lineage pan-leukocytes (CD45) and precursor cells [CD34, human leukocyte antigen-DR (HLA-DR) and terminal deoxynucleotidyl transferase (TdT)].

V- Advanced investigations

a- Quantitative assessment of hTERT by ELISA. ⁽²³⁾

Serum hTERT concentrations will be determined with a polyclonal sandwich ELISA kit. Level expressed in ng/ml using antibody to hTERT which is pre-coated onto plastic micro well strips. The intensity of the developed yellow color is directly proportional to the concentration of hTERT in the sample. hTERT levels are quantified by measuring the absorbance at 450 nm and comparing it against the concentration generated from the standard curve.

b- A quantitative PCR method for measuring telomere length. ⁽²⁴⁾

Genomic DNA from patients will be extracted using conventional methods. Relative telomere length (RTL) will be determined using real-time PCR.

References

1. Burnett AK, Venditti A. Acute myeloid leukaemia. In: Post graduate Haematology. Hoffbrand AV, Catovsky D, Tuddenham E (eds). 6th ed. Blackwell Publishing Ltd, UK. 2011, pp. 415-33.
2. Mrozek K, Heerema N A . Cytogenetics in acute leukemia. *Blood Rev* 2004; 18:115–36.
3. Gross M, Mkrtchyan H, Glaser M, Fricke H J, Hoffken K, Heller A, et al. Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. *Int J Oncol* 2009; 34: 417–23.
4. Pennaneach V, Putnam CD, Kolodner RD. Chromosome healing by de novo telomere addition in *Saccharomyces cerevisiae*. *Molecular Microbiology* 2006; 59: 1357–68.
5. Miller D, Reynolds GE, Mejia R, Stark JM, Murnane JP. Subtelomeric regions in mammalian cells are deficient in DNA double strand break repair. *DNA Repair* 2011; 10: 536–44.
6. Murnane JP. Telomere dysfunction and chromosome instability. *Mutat Res* 2012; 730: 28-36.
7. Charles H. Telomeres, telomerase, and cancer. *N Engl J Med* 2000; 342: 1282-3.

8. Klapper W, Krams M, Qian W, Janssen D, Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. *Br J Cancer* 2003; 89: 713-9.
9. Wong JMY, Collins K. Telomerase maintenance and disease. *Lancet* 2003; 362: 983-8.
10. Bryce LA. Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. *Neoplasia* 2000; 2: 197–201.
11. Sabah M, Robert C, Mary L, Elaine K. Immunohistochemical detection of hTERT protein in soft tissue sarcomas: correlation with tumor grade. *Appl Immunohistochem Mol Morphol* 2006; 14(2): 198-202.
12. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. *Oncogene* 2002; 21(4) : 680–7.
13. Olausson KA, Dubrana K, Domont J, Spano J, Sabatier L, Charles J. Telomeres and telomerase as targets for anticancer drug development. *Crit Rev Oncol Hematol* 2006; 57(3):191-214.
14. Briatore F, Barrera G, Pizzimenti S, Toaldo C, Casa CD, Laurora S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. *Cancer Biol Ther* 2009; 8(10):883–9.
15. Porika M, Tippani R, Bollam SR, Panuganti SD, Thamidala C, Abbagani S. Serum human telomerase reverse transcriptase : a novel biomarker for breast cancer diagnosis. *Int J Clin Oncol* 2011; 16:617–22.
16. Baird DM. New developments in telomere length analysis. *Exp Gerontol* 2005; 40: 363–8.
17. Hartmann U, Brümmendorf TH, Balabanov S, Thiede C, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. *Haematologica* 2005; 90:307-16.

18. Baer MR, Greer JP. Acute myeloid leukaemia in adults. In: Wintrobe's clinical haematology. Greer JP, Foerster J, Luken JN (eds). 12th ed. Lippincott William's and Wilkin's publishers, Philadelphia USA. 2009, pp. 1843 -89.
19. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Elsevier Saunders Company, St Louis. 2006, pp. 797-825 (renal function tests), 604-14 (liver function tests).
20. Howven B. The blood cell count. In: Advanced laboratory methods in haematology. Rawan RM, van Assendelft OW, Perston FE (eds). 1sted. Library of Congress Cataloging, Great Britain. 2002, pp. 19-44.
21. Bates I. Bone marrow biopsy. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 9th ed. Library of Congress Cataloging, London. 2001, pp. 101-14.
22. Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Dacie and Lewis Practical Haematology. Lewis SM, Bain BJ, Bates I (eds). 9th ed. Library of Congress Cataloging, London. 2001, pp. 297-314.
23. Leffell MS. Immunity and immunological assays. In: Laboratory Medicine. Noe DA, Rock RC (eds). 1st ed. Library of Congress Cataloging, USA.. 1994, pp. 75-97.
24. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30(10): e47.

SUMMARY

Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms characterized by a clonal proliferation of myeloid precursors with reduced capacity to differentiate into more mature cellular elements. The response to treatment and overall survival of patients with AML is heterogeneous.

Prognostic factors are urgently needed in order to be able to better predict treatment outcomes. Cytogenetic aberrations are among the most important independent prognostic factors. However, about two thirds of AML patients display a normal karyotype. This group has intermediate disease-free and overall survival, but the clinical outcome of individual patients within this group is still highly variable. Therefore, identification of parameters that allow the good risk patients to be separated from the bad risk ones within this cytogenetically defined group is crucial in order to improve risk-adapted treatment strategies in AML.

In a trial to elucidate the prognostic value of telomere shortening and telomerase activity in AML, telomere length and human telomerase reverse transcriptase (hTERT) were studied in the present study and the results of both were evaluated in relation to each other and to different treatment outcome in AML patients.

Enzyme linked immunosorbent assay (ELISA) and PCR technique were used in our study for evaluation of hTERT and relative telomere length respectively in AML patients. The use of ELISA technique in this study provided an easy, simple and less expensive method for evaluation of gene products if compared to other molecular techniques.

The study included seventy Individuals, twenty healthy subjects as control group and fifty cases of AML. The hTERT levels in the control ranged from 2.04 ng/ml to 11.11 ng/ml. Mean level was 5.06 ± 2.32 ng/ml. serum levels in AML cases ranged from 4.9 ng/ml to 98 ng/ml. Mean level was 43.3 ± 25.4 ng/ml. There was statistically significant higher level of hTERT in patients than controls. Relative telomere length (RTL) in AML patients ranged from 0.01 to 1.1. Mean level was 0.4 ± 0.3 . Mean telomere length in normal subjects was 3.75. There was statistically significant lower RTL in patients than control. There was a negative correlation between serum level of hTERT and the relative telomere length. No significant correlation was detected between RTL and hTERT and age, sex and FAB classification.

The patients were treated according to the standard chemotherapy protocol for induction and they were followed up by bone marrow examination. Nineteen cases achieved CR after induction therapy, percentage of CR was higher in younger age group than in elderly. Fifteen cases died during first 28 days with higher percentage of deaths in the elderly. Seven cases attained partial response either in the form of no restoration of peripheral blood counts and/or bone marrow, percentage of partial response was higher in elderly. Nine cases achieved no response at all. Seven cases are younger than sixty and two cases are elderly, during follow up of cases nine cases who attained remission relapsed, seven cases are younger than sixty while 2 cases are elderly. Mean age was statistically significant lower in patients who achieved remission.

Summary

The median level of hTERT in cases that died during induction was 55.7 ng/ml while in survived cases it was 54.9 ng/ml. Median relative telomere length (RTL) was shorter in cases that died than in survived cases after induction therapy, (RTL was 0.2 and 0.5 respectively). Mean hTERT level in patients who did not achieve remission was statistically significant higher than that in patients who achieved remission. Mean RTL in patients who achieved remission was higher than that in patients who did not achieve remission (.56 and .37 respectively). At the end of the study (after 30 ms) we found that mean hTERT level was statistically significant higher in dead cases than mean level in censored cases (43.33 and 24.75 respectively). Mean RTL was statistically significant higher in censored cases than in dead cases (.725 and .341 respectively).

ROC curve showed that certain hTERT level (57.57 ng/ml) would be considered as a prognostic value that could predict response in AML patients. (Area under the curve (AUC) = 0.603, this means that, in AML patients with value less or equal to 57.57 ng/ml, 60.3% of patients will achieve complete remission. **Sensitivity** of hTERT cut-off value (57.57 ng/ml) as a predictive value for response was **69.2 %**, and **specificity** was **56 %**.

Also ROC curve showed that certain RTL value (0.5) would be considered as a prognostic value that could predict response in AML patients. (Area under the curve (AUC) = 0.556, this means that, in AML patients with value equal or more than 0.5, 55.6% of patients will achieve complete remission. **Sensitivity** of RTL cut-off value (0.5) as a predictive value for response was **50 %**, and **specificity** was **56 %**.

During duration of our study (30 months), number of events was 36 and censored cases were 14. Median survival time for all AML patients in the study was 10 months. Median survival time in elderly patients was shorter than that in younger patients. Median survival time in patients who achieved remission was statistically significant longer than that in those who did not achieve remission (26 ms, 4 ms respectively). Median survival time in relapsed patients was statistically significant shorter than that in non relapsed patients (20 ms, 26 ms respectively).

Median survival time in patients with hTERT level higher than cut-off level was shorter than median survival time in patients with lower value, (5 ms, and 14 ms respectively). There was a statistical significant difference in median survival time in both groups. Median survival time in patients with relative telomere length lower than cut-off value was shorter than median survival time in patients with higher value, (6 ms, and 14 ms respectively). There was a statistical significant difference in median survival time in both groups.

It was found that both relative telomere length and hTERT could be used for predicting treatment outcome in AML patients. This predictive impact of RTL and hTERT may be of help in assessing clinical behavior and outcome in AML patients.

الملخص العربي

سرطان الدم النقوى الحاد يشير إلى مجموعة من الأورام المكونة للدم يتميز بانتشار الخلايا الأولية للنخاع مع انخفاض القدرة على التمايز إلى العناصر الخلوية أكثر نضجاً. الاستجابة للعلاج وفترة البقاء أحياء لمرضى سرطان الدم النقوى الحاد هي متباينة. وهناك حاجة إلى عوامل نذير على وجه السرعة من أجل أن تكون قادرة على التنبؤ بشكل أفضل لنتائج العلاج. الانحرافات الوراثية الخلوية هي من بين العوامل النذير المهمة.

ومع ذلك، حوالي ثلثي المرضى سرطان الدم النقوى الحاد له نمط نووي عادي. هذه المجموعة لديها مؤشر متوسط للبقاء خالية من المرض والبقاء العام، ولكن النتيجة السريرية لهؤلاء المرضى لا تزال شديدة التباين. لذلك، وجب تحديد المعايير التي تسمح لفصل المرضى ذوي معامل خطورة جيد من المرضى ذوي معامل خطورة سيئ ضمن هذه المجموعة من أجل تحسين استراتيجيات العلاج وتكييفها حسب المخاطر في مرضى سرطان الدم النقوى الحاد.

في محاولة لتوضيح قيمة نذير التيلوميراز في مرضى سرطان الدم النقوى الحاد، تمت دراسة طول التيلومير و الناسخ العكسي للتيلوميراز البشري في هذه الدراسة وجرى تقييم النتائج سواء في علاقتها ببعضها البعض و غلاقتها بنتائج العلاج المختلفة للمرضى. تم استخدام تقنية (ELISA) وتقنية PCR في دراستنا لتقييم التيلوميراز و طول التيلومير النسبي على التوالي في المرضى. توفر استخدام تقنية ELISA في هذه الدراسة طريقة سهلة وبسيطة وأقل تكلفة لتقييم المنتجات الجينية إذا ما قورنت التقنيات الجزيئية الأخرى.

وشملت الدراسة سبعين فرداً عشرين أصحاء كمجموعة تحكم وخمسين حالات مرضى سرطان دم نقوى حاد. كان متوسط مستوى التيلوميراز في مجموعة التحكم أقل منه في مرضى سرطان الدم النقوى الحاد وكان الفرق له دلالة كما وجدنا الطول النسبي للتيلومير في المرضى أقل منه في مجموعة التحكم وكان الفرق له دلالة احصائية. كان هناك علاقة عكسية بين مستوى التيلوميراز وطول التيلومير النسبي وتم الكشف عن عدم وجود ارتباط كبير بين كل منهما والعمر والجنس وتصنيف FAB.

تم علاج المرضى وفقاً لبروتوكول العلاج الكيميائي وتم تقييم نتائج العلاج عن طريق فحص النخاع العظمى. حققت تسعة عشر حالة استجابة كلية بعد العلاج الأولى الحثي، كان نسبة الاستجابة الكلية أعلى في الفئة العمرية الأصغر سناً مما كان عليه في كبار السن. خمسة عشر حالات توفيت خلال الشهر الأول مع نسبة أعلى من الوفيات في كبار السن. حققت سبع حالات استجابة جزئية إما في شكل عدم استعادة لتعداد الدم الطرفي و / أو في النخاع العظمى، وكانت النسبة المئوية للاستجابة الجزئية أعلى في كبار السن. حدثت تسع حالات ارتداد للمرض سبع حالات في الفئة العمرية الأصغر وحالتين من كبار السن وكان متوسط عمر من حقق استجابة كلية أقل من متوسط عمر من لم يحقق استجابة كلية كما ان الفرق بين العمريين كان له دلالة احصائية.

Summary

كان متوسط مستوى التيلوميراز في الحالات التي توفيت خلال البحث ٥٥.٧ نانوغرام / مل بينما كان في الحالات التي نجت ٥٤.٩ نانوغرام / مل. كان متوسط طول التيلومير النسبي أقصر في الحالات التي توفت منه في الحالات التي نجت بعد العلاج الحثي

كان متوسط مستوى التيلوميراز في المرضى الذين لم يحققوا استجابة كلية اعلى منه في المرضى الذين حققوا استجابة كلية وكان الفرق ذو دلالة إحصائية. كما كان متوسط الطول النسبي للتيلومير في المرضى الذين حققوا استجابة كلية اعلى من ذلك في المرضى الذين لم يحققوا استجابة كلية و ايضا كان الفرق له دلالة احصائية. كما وجدنا أن متوسط مستوى التيلوميراز أعلى إحصائياً في الحالات التي توفت خلال فترة البحث (٣٠ شهر) من الحالات التي نجت حتى نهاية فترة وكان طول التيلومير النسبي اعلى احصائياً في المرضى الناجين حتى نهاية فترة البحث.

أظهر منحني الورك أن مستوى التيلوميراز (٥٧.٥٧ نانوغرام / مل) له قيمة نذيرية التي يمكن أن تتوقع استجابة المرضى للعلاج. وكانت هذه النقطة الفاصلة (٥٧.٥٧ نانوغرام / مل) لها حساسية بنسبة ٦٩.٢٪، للتنبؤ للاستجابة و لها نسبة خصوصية ٥٦٪.

كما أظهر منحني الورك ان النقطة الفاصلة لطول التيلومير النسبي هي (٠.٥) و هذه النقطة الفاصلة لها حساسية بنسبة ٥٠٪، للتنبؤ للاستجابة و لها نسبة خصوصية ٥٦٪.

خلال مدة دراستنا (٣٠ شهرا)، كان عدد الوفيات ٣٦ وكانت الحالات الناجية حتى نهاية البحث ١٤. متوسط البقاء لجميع المرضى في الدراسة كان ١٠ شهرا. كان متوسط البقاء في المرضى المسنين أقصر من ذلك في المرضى الأصغر سنا. وكان متوسط البقاء للمرضى الذين حققوا استجابة كلية اعلى احصائياً من متوسط بقاء المرضى الذين لم يحققوا استجابة كلية كما ان متوسط بقاء المرضى الذين حدث لهم انتكاسة اقصر احصائياً من المرضى الذين لم يحدث لهم انتكاسة مرضية

كان متوسط بقاء المرضى الذين لديهم مستوى التيلوميراز اعلى من النقطة الفاصلة أقصر احصائياً من متوسط وقت البقاء في المرضى الذين لديهم مستوى التيلوميراز اقل من النقطة الفاصلة. كما كان متوسط البقاء في المرضى الذين لديهم طول التيلومير النسبي أقل من النقطة الفاصلة اقصر احصائياً من متوسط البقاء في المرضى الذين لديهم طول التيلومير النسبي اعلى من النقطة الفاصلة

تبين أن كلا من طول التيلومير النسبي والتيلوميراز يمكن أن يستخدموا للتنبؤ بنتائج العلاج في مرضى سرطان الد النقوى الحاد. هذا التأثير التنبؤي لكل منهما قد يكون عوناً في تقييم السلوك السريري ونتائج المرضى.

طول التيلومير ومستوى الناسخ العكسى البشرى للتيلوميريز فى مرضى سرطان الدم النقوى
الحاد و اثرهما على المحصلة الاكلينيكية

رسالة

مقدمة إلى معهد البحوث الطبية- جامعة الإسكندرية
ايفاء جزئيا لشروط الحصول على درجة

الدكتوراه

فى

طب و باثولوجيا أمراض الدم

مقدمة من

حياة خليفة فضل الله احمد

بكالوريوس الطب و الجراحة - ماجستير أمراض الدم
مدرس مساعد بقسم أمراض الدم - جامعة الإسكندرية

معهد البحوث الطبية
جامعة الإسكندرية
٢٠١٤

المشرفون

موافقون

أ.د. سامية فرج محمد البليسي
أستاذ بقسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

أ.د. هناء عبد المجيد العجان
أستاذ بقسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

د. هالة قاسم سلطان
أستاذ مساعد بقسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

د. امل على النجار
مساعد استشاري بقسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية